Pfizer: Too Cheap To Miss Out

Massimo Giachetti My thesis Pfizer (NYSE:PFE) was one of few pharmaceutical companies which were able to develop the COVID-19 vaccine within a short period, and I was very surprised to find out that the stock currently trades below pre-pandemic levels. Data by YCharts The business looks solid as the revenue mix is diverse across various geographies, diseases and products. Despite recent dip in profitability, it is still stellar and enables the company to pour billions per annum in developing new products. T ...